The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Recce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its RECCE 327 (R237) synthetic antibiotic, which will be used to treat urinary tract infection (UTI) and urosepsis.

The four subjects were dosed by fast infusion, receiving 3,000 milligrams (mg) of R237 over 20 minutes.

The cohort testing was part of a wider program for Recce’s Phase I/II UTI/Urosepsis clinical trial, evaluating the drug at fast infusion rates, and work is now set to begin on data evaluation and review – to be undertaken by an Independent Safety Committee – and recruitment for the next testing cohort.

After that, Recce will progress to a Phase II UTI/Urosepsis efficacy trial for the drug, hoping to establish it as a frontline treatment for these conditions.

CEO James Graham said the results moved Recce one step close to achieving this goal.

“Completing dosing for our latest cohort marks another milestone in our journey advancing R327 as a potential frontline treatment for UTI/Urosepsis,” he said.

“We are dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes globally.”

The value of R237 derives from the fact that administration of antibiotics through rapid intravenous infusions has been shown to impact patient treatment, wait times, and nursing workloads globally.

Recce Pharmaceuticals is trading at 44c.

RCE by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…